Special Issue "Adenoviral Vector-Based Vaccine"
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".
Deadline for manuscript submissions: closed (1 May 2023) | Viewed by 63
Special Issue Editors
Interests: generation of human and nonhuman adenoviral vectors based vaccines for influenza viruses, SARS-CoV-2, tuberculosis and other infectious diseases; evaluation of the humoral and cell-mediated immune responses developed by different vaccine platforms in multiple animal models; evaluation of the vaccine protection efficiency against infectious diseases; using different molecular tools to generate different cell lines, CAR T cells and cancer vaccines
2. Department of Pathology, Faculty of Veterinary Medicine, Benha University, Kalyubia 13736, Egypt
Interests: cancer immunology; cancer models; cancer imaging and molecular biology
Special Issue Information
Dear Colleagues,
Modern molecular and biological techniques have helped scientists to manipulate the genomes of several adenoviruses and use them for therapeutic purposes. Adenovirus vectors have been utilized in vaccine development, gene therapy, and cancer therapy studies in the last few decades.
Adenovirus-vector-based vaccines have many advantages. The safety of adenovirus vectors has been established because they are developed from low- or non-pathogenic strains, the adenovirus nucleic acids do not integrate into the host cell genome, and most adenovirus vectors are replication-defective. Moreover, adenovirus vector vaccines are relatively easy to generate, with the advantage of stimulating both humoral and cell-mediated immune responses against the transgene without using an adjuvant. Therefore, adenovirus vector vaccines are used in many clinical trials, and were recently licensed in humans to face the COVID-19 pandemic.
This Special Issue welcomes the submission of recent studies using adenovirus vector platforms to develop effective vaccines.
Dr. Ekramy Sayedahmed
Dr. Said Elshafae
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- adenovirus-vector-based vaccine
- adenovirus-vector-based influenza vaccine
- adenovirus-vector-based SARS-CoV-2 vaccine
- adenovirus-vector-based vaccine immunity
- adenovirus-vector-based vaccine protection efficacy
- immune response against adenovirus-vector-based vaccine
- adenovirus-vector-based vaccine for infectious diseases
